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Abstract
It has been reported that IDH1 (IDH1R132) mutation was a frequent genomic alteration in grade II and grade III glial tumors
but rare in primary glioblastoma (pGBM). To elucidate the frequency of IDH1 mutation and its clinical significance in Chinese
patients with pGBM, one hundred eighteen pGBMs were assessed by pyro-sequencing for IDH1 mutation status, and the
results were correlated with clinical characteristics and molecular pathological factors. IDH1 mutations were detected in 19/
118 pGBM cases (16.1%). Younger age, methylated MGMT promoter, high expression of mutant P53 protein, low expression
of Ki-67 or EGFR protein were significantly correlated with IDH1 mutation status. Most notably, we identified pGBM cases
with IDH1 mutation were mainly involved in the frontal lobe when compared with those with wild-type IDH1. In addition,
Kaplan-Meier survival analysis revealed a highly significant association between IDH1 mutation and a better clinical
outcome (p=0.026 for progression-free survival; p=0.029 for overall survival). However, in our further multivariable
regression analysis, the independent prognostic effect of IDH1 mutation is limited when considering age, preoperative KPS
score, extent of resection, TMZ chemotherapy, and Ki-67 protein expression levels, which might narrow its prognostic
power in Chinese population in the future.
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Introduction
Primary glioblastoma (pGBM) is highly malignant and the most
common type of primary brain tumors in adults. Regardless of
surgerycombined with radiation therapy and chemotherapy, median
survival for pGBM patients ranges from 12–15 months after GBM
diagnosis [1]. Thus new avenues have to be taken to discover effective
strategies, requiring more insights into aberrant molecular mecha-
nisms relevant to tumor biology and treatment [2]. Over the last
decades, some of the characteristic genomic alterations have been
reported to be associated with the origin and development of
glioblastomas [3]. However, to date, only MGMT promoter
methylation status has been demonstrated to be of clinical
significance in prospective clinical trials in GBM patients [4]. Recent
studies suggestthatIDH1 R132 mutations arepresent in the majority
of common adult gliomas but only occur in small fraction of pGBMs,
and patients with IDH1 mutation have a better outcome than those
with wild-type IDH1 in gliomas [5]. Further studies across the world
have validated the exciting discovery [6,7]. And it has been reported
that patients with IDH1 mutation were also sensitive to Temozolo-
mide (TMZ) in low-grade gliomas [8]. Consequentially, this raises
questions regarding the capacity of IDH1 mutation for use as a
prognostic or predictive marker for customized treatment in glial
tumors in the near future. However, the frequency of IDH1 mutation
and its clinical significance in Chinese patients with pGBM has not
been elucidated systematically.
In the present study, to underscore the potential role of IDH1
mutationinpGBM,118Chinesepatients with pGBMwereassessed
by pyro-sequencing for IDH1 mutation status, and the results were
correlated with clinical characteristics and molecular pathological
factors. IDH1 mutations were detected in 19/118 cases (16.1%). It
should be pointed out that pGBM cases with IDH1 mutation were
mainlyinvolvedinthefrontallobe,andalsoassociated with younger
age, methylated MGMT promoter, high expression of mutant P53
protein, low expression of Ki-67 or EGFR protein. Further Kaplan-
Meier and Cox-regression analyses also demonstrated that IDH1
mutation was a prognostic but not an independent prognostic factor
in Chinese patients with pGBM.
Materials and Methods
Tumor samples
One hundred and eighteen patients with primary GBM from
the department of Neurosurgery at Beijing Tiantan Hospital were
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e30339included in this study. All the patients underwent surgical resection
between January 2006 and December 2009, and subsequently
received radiation therapy and alkylating agent-based chemother-
apy. Tumor tissue samples were obtained by surgical resection
before the treatment with radiation and chemotherapy. Resected
specimens were quick-frozen in liquid nitrogen and kept at 280uC
until nucleic acid extraction. This study was approved by the Ethics
Committee of Beijing Tiantan Hospital and written informed
consent was obtained from all patients. Primary GBM was defined
by two neuropathologists according to Scherer [9]. Only samples
with greater than 80% tumor cells were selected. Clinical details,
including the patient’s sex, age at the time of diagnosis, preoperative
Karnofsky Performance Status (KPS) score, tumor location, extent
of resection, adjuvant chemotherapy, and the recorded date of
disease progression or death were all noted.
DNA pyro-sequencing for IDH1 mutation
Genomic DNA was isolated from frozen tumor tissues by using
the QIAamp DNA Mini Kit (Qiagen). The genomic region
spanning wild-type R132 of IDH1 was analyzed by Pyrophosphate
sequencing using the following primers: 59-GCTTGTGAGTG-
GATGGGTAAAAC-39 and 59-Biotin-TTGCCAACATGACT-
TACTTGATC-39. The PCR analysis was performed in duplicate
in 40 ml reaction volume, containing 1 mlo f1 0mM each forward
and reverse primer, 4 ml1 0 6buffer for, 3.2 ml of 2.5 mM dNTPs,
2.5 U hotstart Taq (Takara) and 2 mlo f1 0mM DNA. The PCR
conditions were as follows: 95uC–3 min; 50 cycles of 95uC–15 s,
56uC–20 s, 72uC–30 s; 72uC–5 min (ABI PCR system 9700).
Single-stranded DNA was purified from the total PCR products
and subjected to pyrosequencing on PyroMark Q96 ID System
(QIAGEN) using the primer 59- TGGATGGGTAAAACCT-39
and EpiTect Bisulfite Kit (QIAGEN).
DNA pyro-sequencing for MGMT promoter methylation
Bisulite modification of the DNA was performed using the
EpiTect Kit (Qiagen). Two primers were used to amplify the
MGMT promoter region: 59- GTTTYGGATATGTTGGGATA
-39 and reverse: 59-biotin-ACCCAAACACTCACCAAATC-39.
The PCR analysis was performed in duplicate in 40 ml reaction
volume, containing 0.5 mlo f1 0mM each primer, 4 ml1 0 6buffer,
3.2 ml of 2.5 mM dNTPs, 2.5 U hotstart Taq (Takara, Madison,
WI) and 2 mlo f1 0 mM bisulphite-treated DNA. The PCR
conditions were: 95uC–3 min; 40 cycles of 95uC–15 s, 52uC–30 s,
72uC–30 s; 72uC–5 min (ABI PCR system 9700). DNA was
purified from the total PCR products using QIAamp DNA Mini
Kit (Qiagen) and subjected to pyrosequencing (PyroMark Q96 ID
System (Qiagen)) using the primer 59-GGATATGTTGGGA-
TAGT-39 in accordance to the manufacturer’s instructions. The
methylation values obtained were averaged across the seven CpG
loci tested within the MGMT promoter. The GBM samples were
considered MGMT promoter methylated with an average
methylation of .10%.
Immunohistochemistry
Immunohistochemistry was performed as described as the
previous report [10]. Briefly, surgical specimens were fixed in
formalin, routinely processed and paraffin embedded. Five
micron-thick sections were prepared, and immunohistochemical
staining with streptavidin-biotin immunoperoxidase assay was
performed using antibodies to Ki-67, MGMT, EGFR, VEGF,
PTEN and mutant P53 (Santa Cruz Biotechnology, Santa Cruz,
CA). The staining intensity was jointly scored by two pathologists
without knowledge of clinical information on a scale of 0 to 3 (0,
negative; 1, slight positive; 2, moderate positive; 3, intense
positive). And scale of 0 and 1 and scale of 2 and 3 indicated
low and high expression of the above proteins, respectively.
Controls without primary antibody and positive control tissues
were included in all experiments to ensure the quality of staining.
Statistical analysis
Two clinical end-points were used to measure clinical outcome,
progression-free survival (PFS) and overall survival (OS). PFS was
defined as the time interval between the date of surgery and the
date of first recurrence. OS was defined as the time interval
between the date of surgery and the date of death. The survival
function curve was calculated with the Kaplan-Meier method and
the difference was analyzed using the two-sided log-rank test.
Correlation of IDH1 mutation with clinicopathologic character-
istics were evaluated by two-sided x2 test or Student’s t-test
between the patient subgroups. Cox proportional hazard regres-
sion analyses were performed to assess the independent contribu-
tion of IDH1 mutation and clinicopathologic variables on survival
prediction. All statistical analysis was performed in the SPSS 13.0
for Windows.
Results
IDH1 mutation in pGBM samples
Of a total of 118 pGBM samples analyzed, 19 (16.1%)
contained an IDH1 R132 mutation located at amino acid residue
132. And 89.5% of them were G395A transition (ArgRHis),
followed by C394A transversion (ArgRSer; 10.5%) (Figure 1A).
Patients with pGBM carrying IDH1 mutations were significantly
younger than those without IDH1 mutations (mean age, 40.3 vs.
48.6 years; p=0.002, t-test; Table 1). And 16/19 pGBM cases
(84.2%) with IDH1 mutation were located in the frontal lobe,
while only 36/99 (36.4%) with wild-type IDH1 were involved in
frontal lobe (p,0.001, two-sided x
2 test; Table 1). The mean
progression-free survival time of pGBM patients with IDH1
mutations was 497.06267.8 days, significantly longer than that of
patients without IDH1 mutations (342.36261.6 days; p=0.026,
log-rank test; Figure 1B). And the mean overall survival time of
pGBM patients with IDH1 mutations was 568.56264.2 days,
significantly longer than that of patients without IDH1 mutations
(457.76291.7 days; p=0.029, log-rank test; Figure 1B).
IDH1 mutation was associated with MGMT promoter
methylation status, and Ki-67, EGFR, mutant P53 protein
expression levels
MGMT promoter methylation was assessed by pyrosequencing
in 77 pGBMs. The Ki-67, MGMT, EGFR, PTEN and mutant
P53 protein expressions were analysed by immunohistochemical
staining in 115 pGBMs. VEGF protein expression was also
assessed by immunohistochemical staining in 64 pGBM samples.
Representative antibody stainings for Ki-67 with scale 0–3 are
shown in Figure 2. Correlations of IDH1 mutation with Ki-67,
MGMT, EGFR, VEGF, PTEN and mutant P53 expression status
in pGBMs are analysed by two-sided x
2 test. As shown in Table 1,
IDH1 mutation was associated with methylated MGMT promoter
(p=0.015), low expression of Ki-67 (p=0.018) or EGFR
(p=0.012) and high level of mutant P53 proteins (p=0.022), but
not with MGMT, VEGF and PTEN expression levels.
The independence of IDH1 mutation as a prognostic
factor was limited in pGBM patients
We first conducted univariate cox regression analysis using
clinical and genetic variables for the total 118 Chinese patients
IDH1 Mutation in pGBMs
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of resection, TMZ chemotherapy, Ki-67 protein expression level,
and IDH1 mutation were statistically associated with PFS and OS,
while sex and MGMT promoter methylation were not associated
with PFS and OS (Table S1). Furthermore, the multivariable
regression analysis and stepwise variable selection were then used
to evaluate the independent prognostic value of these clinicopath-
ologic factors on patient survival. The independence of IDH1
mutation as a prognostic factor was limited in 118 pGBM patients
when considering gender, age, preoperative KPS score, extent of
resection, TMZ chemotherapy, and Ki-67 protein expression level
(HR, 0.62; 95%CI, 0.32–1.22; p=0.17 for OS; HR, 0.62; 95%CI,
Figure 1. IDH1 mutations in pGBMs. All mutations by pyro-sequencing analysis were located at codon 132. And 89.5% of them were G395A
transition (ArgRHis), followed by C394A transversion (ArgRSer; 10.5%) (A). Kaplan-Meier Survival Analysis showed that pGBM patients carrying an
IDH1 mutation (dotted line) had significantly longer progression free survival (p=0.026; log-rank test) and overall survival (p=0.029; log-rank test) (B).
doi:10.1371/journal.pone.0030339.g001
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independent indicator than IDH1 mutation in our GBM samples.
We also provided a multivariable cox model without Ki-67 to re-
evaluate the association between IDH mutation and outcomes
(Table S2). And as shown in Table S2, the P values of IDH1
mutation in Multivariate cox model were reduced to 0.09 (Overall
Survival) and 0.05 (Progression-Free Survival) regardless of Ki-67
expression.
Discussion
IDH1 mutations were initially discovered in a subset of GBMs
by large-scale sequencing [11], and nearly 93% of IDH1
mutations are of the R132H variant. However, subsequent studies
reported that IDH1 mutations were detected at much higher
frequencies ranged from 60% to 80% in WHO grades II and III
gliomas as well as in secondary GBMs. In contrast, it has been
reported only 5 to 10% of pGBMs were accompanied with IDH1
mutations [12]. IDH1 mutations are an early event in tumori-
genesis, and an independent favorable prognostic marker in
human gliomas [13]. In the present study, IDH1 (IDH1R132)
mutations existed in 16.1% pGBM samples among a large cohort
of 118 Chinese patients. It is suspected that pGBM with IDH1
mutation may evolve from relative low grade glioma although
without surgery history. In China, low grade gliomas offer a
significantly higher percentage than that of Western countries.
From the above, the high percentage of low grade gliomas in
China may be the reason of higher frequency of IDH1 mutation in
the Chinese pGBM population. Besides, 89.5% of IDH1
mutations were G395A transition (ArgRHis, R132H), followed
by C394A transversion (ArgRSer, R132S; 10.5%). In accordance
with previous studies, IDH1 mutations were more likely to occur
in younger patients and also predicted a better clinical outcome in
pGBMs at our institute.
Enhanced cellular proliferation is a fundamental feature of the
growth of GBM [14]. The epidermal growth factor receptor
(EGFR) is overexpressed and induces proliferation in multiple
cancers including pGBM [15,16]. And Ki-67 is a widely accepted
marker for cell proliferation in daily pathologic practice [17,18]. In
the present study, we discovered that there was significant lower
Ki-67 and EGFR protein expression in the pGBM samples with
mutated IDH1 when compared with those with wild-type IDH1.
Therefore, the correlation between IDH1 mutation and a better
clinical outcome in pGBM patients may be associated with the low
proliferation rate accompanying IDH1 mutation.
Previously, it has been demonstrated that most (80%) of the
GBM samples with mutated IDH1 or IDH2 genes also had a
mutation of p53 gene [19]. Consistent with this notion, in this
study, we identified pGBM samples with IDH1 mutations showed
a much higher expression level of mutant P53 protein. It is well
Table 1. Clinical and molecular pathology features of pGBM samples in association with IDH1 mutations.
IDH1 mutation IDH1 wild type p value*
No. of cases 19 (16.1%) 99 (83.9%)
Gender (Female/Male) 8/11 36/63 0.796
Age at diagnosis (year) 40.369.3 48.6613.2 0.002
{
MGMT promoter methylation (Unmethylated/Methylated) 4/8 48/17 0.015
MGMT (Low/High) 8/11 38/58 1.000
Ki-67 (Low/High) 12/7 31/65 0.018
EGFR (Low/High) 10/9 22/74 0.012
PTEN (Low/High) 0/19 5/91 0.589
VEGF (Low/High) 5/7 17/35 0.737
Mutant P53 (Low/High) 1/18 30/66 0.022
Tumor location (Location/Total)
Frontal lobe 16/19 36/99 ,0.001
Temporal lobe 2/19 39/99 0.017
Parietal lobe 0/19 13/99 0.124
Occipital lobe 0/19 1/99 1.000
Insula 1/19 1/99 0.297
Corpus callosum 0/19 3/99 1.000
Others 0/19 6/99 0.588
*Two-sided x test.
{Student’s t-test.
doi:10.1371/journal.pone.0030339.t001
Figure 2. Representative antibody stainings for Ki-67. IHC
results of Ki-67 are shown on a scale of 0 to 3 (0, negative (A); 1, slight
positive (B); 2, moderate positive (C); 3, intense positive (D)). And scale
of 0 and 1 and scale of 2 and 3 indicated low and high expression,
respectively.
doi:10.1371/journal.pone.0030339.g002
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mutant p53 has been testified to promote the tumor growth [21].
Due to the better prognosis in the group with IDH1 mutation, it
was interesting that mutant P53 protein was at a higher expression
level in the samples with mutated IDH1. The inherent mechanism
needs further investigation.
Accumulating evidences showed that epigenetic silencing of
MGMT by promoter methylation and its association with
improved survival in GBM patients treated with alkylating agents
including Temozolomide [22,23]. Recent studies also proved that
IDH1 or IDH2 mutations predicted longer survival and response
to temozolomide in low-grade gliomas [8]. However, the
association of IDH1 mutation with MGMT promoter methylation
or protein expression has not been systematically investigated in
pGBMs. In our cases, the pGBM samples with mutated IDH1
showed a higher MGMT promoter methylation compared to
those with wild-type IDH1. However, no correlation was identified
between IDH1 mutation status and MGMT protein expression
levels in pGBM samples. The oncogenic function and molecular
pathway of IDH1/2 have not been fully understood yet.
Nevertheless, the most recent studies further suggested that
IDH1/2 mutations were associated with a distinct DNA
hypermethylation phenotype in gliomas [24]. Therefore, it is
possible that IDH1/2 mutations were involved in oncogenesis by
the inactivation of tumor suppressor genes through promoter
hypermethylation.
To date, few reports pointed out that IDH1 mutations were
associated with tumor locations [7]. In our present study, for the
first time to our knowledge, we found that the majority of pGBMs
(84.2%) with IDH1 mutations were located in the frontal lobe,
with a much higher percentage than those with wild-type IDH1
(36.4%). This phenomenon indicates that there might be a direct
relationship between IDH1 mutations and tumor location. And
the mechanisms underlying the above phenomenon remain to be
validated and deciphered on more samples and researches.
Almost every research on IDH1 mutation commonly reported
that IDH1 mutation was a strong prognostic indicator [5–8].
Multivariable regression analysis has shown that IDH1 mutation is
an independent prognostic factor in anaplastic oligodendroglial
tumors when referring to type of surgery, KPS, age, location, the
central histology review diagnosis, endothelial abnormalities,
necrosis, and the molecular factors such as 1p/19q loss, EGFR
amplification, and MGMT promoter methylation [25]. Sanson et
al. also indicated that IDH1 mutations predicted a better outcome
in grade 2, grade 3, and grade 4 gliomas after adjustment for
grade, age, MGMT status, genomic profile, and treatment in the
multivariate regression model [13]. In our study, 118 pure pGBM
samples were subjected to IDH1 mutation testing and used for the
following survival analysis. And our study also kept in line with the
previous studies in univariable regression model. Furthermore, we
make initial selection of prognostic factors using univariable
regression analysis, and only those with potential association with
survival were included in our further multivariable regression
model. Our multivariable regression analysis showed that the
independence of IDH1 mutation as a prognostic factor was limited
in 118 pGBM patients when considering age, preoperative KPS
score, extent of resection, TMZ chemotherapy, and Ki-67 protein
expression level. In our previous study, we reported that Ki-67 was
a very strong prognostic indicator in our center [26]. And Ki-67 is
an independent prognostic factor in the multivariable regression
model including IDH1 mutation. When Ki-67 was removed from
the multivariable regression model, the P values of IDH1 mutation
in multivariate regression model were reduced to 0.095 (Overall
Survival) and 0.071 (Progression-Free Survival). These findings
pointed out that the better clinical outcome conferred by IDH1
mutations was the results of younger age, low expression of Ki-67
protein, or any other molecular alterations associated with IDH1
mutations. This might indicate the limitation of IDH1 mutation as
an independent prognostic factor in Chinese patients with pGBM
in the future.
In summary, our study confirms that IDH1 mutation is a strong
prognostic biomarker for a favourable clinical outcome of Chinese
patients with pGBM. Our data underscored the associations
between IDH1 mutation status and younger age, methylated
MGMT promoter, high expression of mutant P53 protein, low
expression of Ki-67 or EGFR protein in pGBM samples. Most
notably, we identified that IDH1 mutation mainly occurred in
pGBM cases which were located in the frontal lobe. Furthermore,
IDH1 mutation was not an independent prognostic indicator in
the multivariable regression model, which might narrow its
prognostic power in Chinese pGBM patients in the future. This
raises questions regarding the capacity of this test as an objective
and reproducible biomarker for customized treatment in individ-
ual cases.
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